RCaz/eu-funding-proposals-sft huggingface dataset:
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'Concept and Approach' section for a Fourth Framework proposal on 'New immuno-pharmaco-toxicological model: human reconstructed epidermis containing langerhans cells'.

assistant: **Concept**

The effort aiming at the use of improved reconstructed skin models as an alternative to animal testing has considerably increased in order to meet the January 1, 1998 deadline (Directive 93/35 EC) at which it will be prohibited in the European Union to sale cosmetic products containing ingredients or combinations of ingredients which have been tested on animals. A major problem, to meet the above requirements, remains the evaluation of new compounds for their potential to cause allergic contact dermatitis (sensitization), which still requires the use of in-vivo tests, since the only industrially produced European model of reconstructed human epidermis is composed of keratinocytes only. A reconstructed human epidermis composed of keratinocytes, melanocytes and Langerhans cells (LC) would considerably enlarge its field of application and provide for the first time a model to be used not only for immuno-pharmaco- toxicological studies in the cosmetic, pharmaceutical, and chemical industry, but also in basic research to study the complex mechanisms of cell-cell interaction in the epidermis. The objective of the present shared-cost RTD project is to develop an in-vitro biotechnical model for immuno-pharmaco- toxicological studies by introducing Langerhans cells into human reconstructed epidermis. For the first time, a reconstructed human epidermis will comprise, as in-vivo, keratinocytes, melanocytes and Langerhans cells. Scientists from four internationally recognized research teams with complementary competence in the fields of LC research and in-vitro skin models will cooperate to realise the four major tasks of this project which include: (i) the definition of culture and maintenance conditions avoiding the spontaneous migration of LC, (ii) the identification of LC that
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the 'Expected Impact' section for the project 'MEsenchymal stem cells to Reduce Liver INflammation' (MERLIN), addressing dissemination and exploitation.

assistant: **Impact**

Prevalence of liver disease is c6% (29 million people) in the EU with mortality rates from chronic liver diseases estimated at 14.3 per 100.000 in the EU-25 in 2004. Most liver diseases have a significant inflammatory component that underpins liver damage and fibrogenesis, yet current therapies have limited effectiveness. Safe novel anti-inflammatory therapies would satisfy a large unmet need for inflammatory liver conditions such as primary sclerosing cholangitis (PSC). Mesenchymal Stromal Cells (MSC) are a mixed population of plastic-adherent (PA) cells isolated from bone marrow, umbilical cord and adipose tissue. Preclinical studies show that intravenous administration of PA-MSC reduces liver inflammation/damage, however only one MSC-based clinical study has been reported to date.MERLIN will examine if MSC can safely reduce biliary damage in mouse models followed by a clinical study in patients with PSC. We have identified an antibody (S2) that isolates comparable MSC from human & mouse marrow, enabling testing of pure functionally distinct cell S2+ & S2- and PA-MSC populations. We will use the world’s first GMP-compliant non-bead-based cell sorter to select S2+ MSC to comply with future therapeutic regulatory requirements. MERLIN partners will use novel methods to enhance MSC efficacy in PSC - by reducing immune clearance of MSC & by promoting MSC functionality & localisation in vivo.We will assess if MSC sub-sets exert differing levels of control upon liver inflammation in pre-clinical models, as well as defining their proliferation and mechanism of action. We will develop entirely novel biomarkers for PSC within the disease pathway pre and post cell infusion. The optimal combination of MSC sub-set and “efficacy enhancement”, will be selected for progression to a P
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft the 'Objectives and Scope' section of a Seventh Framework proposal for the project 'Composing Learning for Artificial Cognitive Systems'.

assistant: **Objectives**

One of the aspirations of machine learning is to develop intelligent systems that can address a wide variety of control problems of many different types. However, although the community has developed successful technologies for many individual problems, these technologies have not previously been integrated into a unified framework. As a result, the technology used to specify, solve and analyse one control problem typically cannot be reused on a different problem. The community has fragmented into a diverse set of specialists with particular solutions to particular problems. The purpose of this project is to develop a unified toolkit for intelligent control in many different problem areas. This toolkit will incorporate many of the most successful approaches to a variety of important control problems within a single framework, including bandit problems,  Markov Decision Processes (MDPs), Partially Observable MDPs (POMDPs), continuous stochastic control, and multi-agent systems. In addition, the toolkit will provide methods for the automatic construction of representations and capabilities, which can then be applied to any of these problem types. Finally, the toolkit will provide a generic interface to specifying problems and analysing performance, by mapping intuitive, human-understandable goals into machine-understandable objectives, and by mapping algorithm performance and regret back into human-understandable terms.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain the overall concept, methodology and approach for the project 'Lighthouse: Lighting the way for European scale-ups' (2014-2020).

assistant: **Concept**

Lighthouse sets a standard on developing cross border connections within and beyond Europe. The project lights the way for startups within Europe by organising 8 Deep Dive Weeks in 4 ecosystems: Berlin, Dublin, Lisbon and the Baltics – meeting over 1600 different ecosystem players in specific themes such as fintech, refugee tech, e-gov, IoT, etc - and culminating with a Top 10 Lighthouse Award in London each year. Lighthouse will support directly over 120 startups to meet key people (investors, corporates, technological experts, media, customers, talent, etc.) in each of these ecosystems through matchmaking, 1-on-1 mentoring, workshops and many other activities.Furthermore, the best of the best of the selected startups will receive the chance to take part in our Europass programme - taking them to 8 of the biggest European tech events; as well as 1 week scouting missions to Silicon Valley, New York and Israel to accelerate their positioning as global players.Lighthouse’s top-notch support activities prepare startups to take advantage of the opportunities in external markets as well as providing qualified introductions to key players in new ecosystems: which all contributes to increased market success. In concrete expected impact, the project will help selected startups to obtain +2000 investment, partnership or customers leads, 500 new international customer leads, develop +100 adapted products/services to new markets, raise collective turnover by 50%, create +500 new jobs, raise +€50m in total investment and many more direct and serendipitous results.Lighthouse does not happen in a vacuum - its structure enables perfect integration with all Startup Europe activities - especially within Deep Dive Weeks. This exploits synergies between Lighthouse, Startup Europe and all
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the novelty, innovation potential and advance beyond the state of the art for 'Intelligent Car Support' (2007-2013).

assistant: **Innovation**

Safe, clean and efficient mobility is a concern for all citizens and contributing to the deployment of ICT solutions aimed at this objective is of interest to all Europeans. eSafety is a joint industry-public sector initiative driven by the European Commission and co-chaired by ERTICO – ITS Europe and ACEA, to promote the development, deployment, and use of Intelligent Integrated Safety Systems to enhance road safety in Europe. With the launch of the Intelligent Car Initiative in 2006 whose objective is to improve the quality of the environment by supporting ICT solutions for safer, smarter and cleaner mobility of people and goods, the eSafety Forum became the first pillar of the Intelligent Car Initiative and extended its focus to those ITS systems supporting cleaner and smarter mobility.Intelligent Car Support is a 36 month Support Action with the objective to support the implementation of actions and recommendations resulting from the work of the eSafety Forum and the Intelligent Car Initiative. This includes support to The eSafety Forum  and its constituencies, strengthening the eSafety cooperation among stakeholders , support the development of the Implementation Road Map for all eSafety systems, contribute to the implementation process of the European eCall system by promoting the eCall toolbox and by supporting the European eCall Implementation Platform, support the i2010 initiative in particular the activities dealing with user outreach and deployment of smarter, safer and cleaner vehicles in the future, launch minor studies on topics identified and endorsed by the eSafety Forum.Intelligent Car Support will establish a Secretariat that will be a key contact point for all stakeholders. It will organise major eSafety Forum events in close cooperation with the Euro
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the 'Expected Impact' section for the project 'Human monoclonal antibodies from a library of hybridomas' (HYBLIB), addressing dissemination and exploitation.

assistant: **Impact**

Introduciton: Unlike monoclonal antibodies from hybridomas, recombinant antibodies from bacteria usually suffer from poor stability and yield. Due to surface displayed antibody molecules, recombinant antibodies are easily screened, though. (WP1) In order to combine both advantages, we plan to construct a library of >10(+6) different hybridomas by consecutive homologous and specific recombinations, with all of the hybridomas descending from one single cell. Each dell displays >100.000 of its" specifi c antibody molecules on the cell surface. Therefore, the library should be easily screened fo low to medium affinity human antibodies specific for almost all antigens. (WP2) Antibodies of higher affinities will be generated by the apparatus responsible fo r somatic hypermutations currently being deciphered, whereby FACS-screening offers an especially easy method to compare affinities. (WP3) The ancestor cell line of our antibody library is engineered to emit signals in response to antigen binding, thus a llowing for the labelling detection of antigen-specific antibodies. Outlook: The combined efforts described above might evolve into a method that supersedes the current state of the art in the production of monoclonal antibodies."
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain how 'LIfetime measurements with Solid Active targets' goes beyond current state-of-the-art under Horizon 2020.

assistant: **Innovation**

The coexistence of single-particle and collective degrees of freedom in atomic nuclei gives rise to various exotic phenomena. In nuclei with very asymmetric proton-to-neutron ratios, the strong nuclear interaction drives shell evolution which alters the orbital spacing, and in some cases even the ordering present in stable nuclei. In the absence of large gaps between orbitals, nuclei can take on non-spherical shapes and their excitations proceed through coherent and collective motion of many nucleons. Where and how collectivity emerges from the single-particle dynamics of protons and neutrons is an open question in nuclear structure physics that will be addressed with LISA in a unique way.The aim of the LISA (LIfetime measurements with Solid Active targets) project is to develop a novel method for lifetime measurements in atomic nuclei. Lifetimes probe the collectivity of a nucleus through its electromagnetic transition properties. The experimental approach is based on active solid targets and will dramatically enhance the scope of measurements of excited-state lifetimes and thus transition probabilities achievable in exotic nuclei. Coupled to state-of-the-art gamma-ray tracking detectors such as AGATA, this novel instrument will overcome the present challenges of lifetimes measurements with low-intensity beams of unstable nuclei.LISA will exploit the unique capabilities of FAIR, the future European fragmentation facility set to deliver the most exotic and highest intensity radioactive ion beams. LISA will greatly expand the physics program for nuclear structure studies at FAIR. Through the measurements made possible by LISA, our understanding of key aspects of single-particle and collective structures and their interplay will become much more developed. The results wil
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'State of the Art and Innovation' section for a Seventh Framework proposal on 'Ultracold Bose-Fermi Mixtures of Metastable Helium'.

assistant: **Innovation**

Experiments using Bose-Einstein condensates (BEC) of ultracold atoms have demonstrated the quantum mechanical similarities between ultracold bosonic atoms and photons of light.  In addition, research using ultracold fermionic atoms has shed light on other interesting and/or unsolved phenomena, such as the pairing of electrons in superconductors and the mechanisms of high Tc superconductivity.  Helium has both stable bosonic (4He) and fermionic (3He) isotopes that may be cooled to quantum degeneracy in a metastable electronic excited state (He*), thus making it ideally suited for the study of the overlap between the fields of ultracold atomic gases, quantum optics and condensed matter.    He* offers a major advantage over other atomic species due to the large internal energy (~20 eV) stored in each atom.  Whereas the detection of ultracold atoms typically relies on optical means that are limited in resolution and efficiency, He* atoms dropped onto a microchannel plate are precisely located in time and space due to the de-excitation of their internal energy.  In groundbreaking experiments, the bunching of bosonic atoms, a phenomenon predicted for photons, has been observed using bosonic 4He*.  Remarkably, the corresponding anti-bunching of fermionic 3He* atoms, with no direct optical analogy, was also observed.        Incorporating the capacity to trap and cool fermionic 3He* into an existing 4He* BEC  apparatus will open the door to many new opportunities.  For example, bosons within a Bose-Fermi mixture may mediate interactions between fermions and play the role of the phonons in a BCS superconductor.  Moreover, Bose-Fermi mixtures in optical lattices promise a unique opportunity for the study of condensed matter systems, and the detection capability afforded by the He*
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write clear, measurable objectives and define the scope for the project 'In-vitro system for mammalian miRNA function' (2007-2013) under Seventh Framework.

assistant: **Objectives**

Over the past decade, micro (mi) RNAs have emerged as key regulators of gene expression. Many miRNAs have been linked to diseases, such as cancer or diabetes. MiRNAs bind to specific sequences in the 3’-untranslated region (UTR) of mRNAs, thereby causing inhibition of translation and/or mRNA degradation. However, the detailed molecular mechanism and the factors involved in miRNA-mediated gene silencing are still incompletely understood. The primary research objective of the current proposal is the generation of a novel mammalian in-vitro system that will allow a detailed biochemical dissection of the molecular mechanisms underlying medical relevant miRNA-guided gene silencing. In particular, we will characterize repression mediated by the tumorsuppressor miRNA let-7. We will elucidate the role of cis- and trans-acting factors in miRNA mediated repression and use the system to purify native miRISC-RNP-complexes (Ribonucleoprotein-complexes) and subsequently identify and characterize the components of the complex. Thus, the knowledge gained from this proposal will enhance our understanding of miRNA function and provide novel insights into the role of RNA metabolism in disease, which will be applicable to the development of novel diagnostic and therapeutic strategies targeting miRNA-associated pathologies.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an executive summary for the EU project 'Disruptive  materials, technologies & approaches to unravel the role of Astrocytes in brain function and dysfunction: towards to Glial interfaces' (ASTROTECH) targeting Horizon 2020.

assistant: **Abstract**

The past four decades demonstrated that non-neuronal cells, called astrocytesare emerging as crucial players for brain function & dysfunction. A major obstacle of previous and current initiatives on Neurotechnologiesis a lack of focus on astrocytesand most of the tools used to probe and sense astrocytes are derived from those developed to study neurons. ASTROTECH will create and develop the field of Glial Engineering, to provide a consistent range of tools to record, study, and manipulate astrocytes in the healthy and diseased brain. ASTROTECH will train 15 Early Stage Researchers (ESRs) on research, training and complimentary skills aiming at: engineering biomaterials and nanostructured interfaces to provide in vivo-like in vitro models for controlled & reliable studies of astrocytes in vitro; fabrication and characterization of nanostructured devices for stimulation, recording and biosensing of astrocytes; optogenetics tools, optoelectronic device &photonic methods for precice and cell selective stimulation of astrocytes; computationalapproaches to describe and predict neuron-astrocytes interactions.The training on state-of-the-art biomaterials interfaces, electronic, photonic devices will be combined with in depth knowledge on optogenetics, neuroscience, glial physiology and biology and computational methodsto validate the developed tools in vitro, ex vivo, in silico & in pathological models of glioma, ischemia, epilepsy and depression.The ASTROTECH network combines 11 beneficiaries and 14 partners belonging to 9 European and Non-EU countries Academia, Public Research Centersand industrial labs, that combines interdisciplinary, intersectoral and soft skills knowledges where the private sector is highly representedand covers every step “from benchside to bedside” of t
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'Concept and Approach' section for a Sixth Framework proposal on 'Study of the generation of CD8 memory T cells against soluble proteins: A step toward a new vaccine design?'.

assistant: **Concept**

The presence of long-lasting CD8 T cell memory is crucial for protection against re-infection by many pathogens. For this reason, vaccination must aim to generate CD8 memory T cells. However, at present the generation of such cells is only achieved by vacc ination with live vaccines. These vaccines utilize attenuated viral strains which can be very difficult to generate and which can present safety hazards. Therefore, it is important to identify new ways of making safe vaccines able to generate strong CD8 me mory cells against soluble proteins. We have previously shown that we can generate strong primary CD8 responses against soluble proteins by co-administrating a natural adjuvant, IFN-a/b. These responses are generated by cross-priming and are independent of CD40. However before this approach can be applied to the development of new vaccines, some fundamental questions must be addressed. The aim of this project is to address the most important of these questions:1)To characterize, in depth CD8 memory cells ge nerated against soluble proteins by cross-priming compared to those generated after viral or bacterial infection against the same antigen2) To study the effect of antigen localisation on the development of memory CD8 T cells. The effect of the route of imm unization on the development of subsequent memory CD8 T cells will be evaluated.3) To identify the subsets as well as the activation status of dendritic cells required for the generation of long-lasting CTL responses.4) To study the effect of the tissue-or igin of the DC in the imprinting of the memory cells All together, this project should allow a better understanding of how to generate potent memory cells by cross-priming as well as providing some insights of the conditions in which dendritic cells can al lo